[go: up one dir, main page]

AR047972A1 - Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. - Google Patents

Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.

Info

Publication number
AR047972A1
AR047972A1 ARP050100653A ARP050100653A AR047972A1 AR 047972 A1 AR047972 A1 AR 047972A1 AR P050100653 A ARP050100653 A AR P050100653A AR P050100653 A ARP050100653 A AR P050100653A AR 047972 A1 AR047972 A1 AR 047972A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
obtaining
bencimidazol
derived
formula
Prior art date
Application number
ARP050100653A
Other languages
English (en)
Inventor
Takanobu Kurolta
Hiroteru Sakamoto
Mami Ojima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR047972A1 publication Critical patent/AR047972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente se refiere a un compuesto representado por la formula (1) en la cual R1 es un grupo representado por la formula (2): donde R2, R3, R4, R5, R6, R7 y R8 son independientemente un átomo de H o un alquilo C1-6, o una sal del mismo. El compuesto de la presente resulta de utilidad como agente para la profilaxis o tratamiento de enfermedades circulatorias tales como hipertension y similares y enfermedades metabolicas tales como diabetes y similares. Proceso de obtencion y composiciones farmacéuticas.
ARP050100653A 2004-02-25 2005-02-23 Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. AR047972A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof

Publications (1)

Publication Number Publication Date
AR047972A1 true AR047972A1 (es) 2006-03-15

Family

ID=34858222

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050100653A AR047972A1 (es) 2004-02-25 2005-02-23 Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
ARP140100236A AR094588A2 (es) 2004-02-25 2014-01-27 Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140100236A AR094588A2 (es) 2004-02-25 2014-01-27 Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica

Country Status (35)

Country Link
US (3) US7157584B2 (es)
EP (3) EP1857457B1 (es)
JP (2) JP4256852B2 (es)
KR (1) KR101080029B1 (es)
CN (2) CN100503605C (es)
AR (2) AR047972A1 (es)
AT (2) ATE370136T1 (es)
AU (1) AU2005214271B8 (es)
BE (1) BE2012C025I2 (es)
BR (2) BRPI0507984B8 (es)
CA (1) CA2557538C (es)
CY (5) CY1107008T1 (es)
DE (3) DE602005016162D1 (es)
DK (3) DK1718641T3 (es)
ES (3) ES2388945T3 (es)
FR (1) FR12C0034I2 (es)
HK (2) HK1098472A1 (es)
HR (3) HRP20070510T3 (es)
HU (1) HUS1200008I1 (es)
IL (1) IL177533A (es)
LU (1) LU91962I2 (es)
MA (1) MA28478B1 (es)
ME (2) ME01089B (es)
MY (1) MY142807A (es)
NL (1) NL300802I2 (es)
NO (2) NO332344B1 (es)
NZ (1) NZ549755A (es)
PL (3) PL2119715T3 (es)
PT (3) PT2119715E (es)
RS (3) RS50537B (es)
RU (2) RU2501798C2 (es)
SI (3) SI1718641T1 (es)
TW (1) TWI336702B (es)
WO (1) WO2005080384A2 (es)
ZA (1) ZA200607241B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
SI1830869T1 (sl) 2004-12-24 2013-12-31 Spinifex Pharmaceuticals Pty Ltd Postopek zdravljenja ali profilakse
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
PE20061195A1 (es) * 2005-03-30 2006-12-21 Takeda Pharmaceutical Derivado de bencimidazol como antagonista de angiotensina ii
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
CA2646379C (en) * 2006-03-20 2014-12-23 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
WO2008041663A1 (en) * 2006-09-25 2008-04-10 Takeda Pharmaceutical Company Limited Medicinal package
US9066936B2 (en) * 2007-03-28 2015-06-30 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
US20110038898A1 (en) * 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
EP2310385B1 (en) 2008-07-31 2017-06-07 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
JP5575137B2 (ja) * 2008-10-22 2014-08-20 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ME02531B (me) 2010-05-11 2017-02-20 Janssen Pharmaceutica Nv FARMACEUTSKE FORMULACilE KOJE OBUHVATAJU DERIVATIVE 1 - (BE TA- D- GLUKOPIRANOZ IL)-2- TIENILMETILBENZENA KAO SGLT INHIBITORE
WO2012090043A1 (en) * 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
CN102603723B (zh) 2011-01-20 2014-10-08 江苏豪森医药集团有限公司 阿齐沙坦有机胺盐及其制备方法和用途
CA2840818C (en) 2011-02-08 2018-12-11 Jubilant Life Sciences Limited An improved process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
DK2697218T3 (en) 2011-04-13 2016-07-25 Janssen Pharmaceutica Nv PROCESS FOR THE PREPARATION OF COMPOUNDS useful as inhibitors of SGLT2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042066A1 (en) * 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
US20130158080A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating hypertension in black patients
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
CN104039779B (zh) * 2012-01-14 2016-08-24 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
IN2014DN06964A (es) * 2012-02-02 2015-04-10 Ranbaxy Lab Ltd
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
US20150291574A1 (en) * 2012-07-09 2015-10-15 Bandi Parthasaradhi Reddy Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
US9624207B2 (en) 2012-08-27 2017-04-18 Hetero Research Foundation Polymorphs of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CN103709154B (zh) * 2012-09-28 2016-06-15 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
EP2906654B1 (en) * 2012-10-09 2020-04-08 Avery Dennison Corporation Adhesives and related methods
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
WO2015051546A1 (zh) * 2013-10-12 2015-04-16 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
WO2016145622A1 (zh) 2015-03-18 2016-09-22 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
CN108135886A (zh) * 2015-07-29 2018-06-08 塔科达有限责任公司 用于糖尿病性肾病治疗的pde4抑制剂
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN112110909A (zh) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
WO2018010622A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 化合物的晶型及其制备方法、组合物和应用
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
WO2018064945A1 (zh) * 2016-10-08 2018-04-12 武汉朗来科技发展有限公司 药物组合物
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN112567469B (zh) * 2018-06-14 2023-11-07 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
KR20200057662A (ko) 2018-11-16 2020-05-26 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
JP7573272B2 (ja) 2019-02-15 2024-10-25 国立大学法人東北大学 １，３－ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
CN118284605A (zh) 2021-12-28 2024-07-02 亚克医药株式会社 化合物、血管紧张素ii第1型受体拮抗剂及医药组合物
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물
TW202432121A (zh) * 2022-11-24 2024-08-16 大陸商上海雲晟研新生物科技有限公司 包含美阿沙坦鉀與鈣通道阻滯劑的藥物組合物、及其製備方法及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) * 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
PL360398A1 (en) 2000-07-13 2004-09-06 Takeda Chemical Industries, Ltd. Lipid-rich plaque inhibitors
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
PL371319A1 (en) 2002-01-11 2005-06-13 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
PL2119715T3 (pl) 2012-10-31
EP2119715A1 (en) 2009-11-18
CN101381366A (zh) 2009-03-11
CN101381366B (zh) 2011-06-15
HRP20120667T1 (en) 2012-09-30
SI1857457T1 (sl) 2010-01-29
JP2005272451A (ja) 2005-10-06
SI1718641T1 (sl) 2007-12-31
CY1109610T1 (el) 2014-08-13
HRP20120667T2 (hr) 2012-11-30
US7572920B2 (en) 2009-08-11
ES2388945T3 (es) 2012-10-22
KR20070020411A (ko) 2007-02-21
NZ549755A (en) 2009-04-30
NL300802I2 (es) 2016-05-18
NO332344B1 (no) 2012-09-03
MA28478B1 (fr) 2007-03-01
JP4256852B2 (ja) 2009-04-22
BRPI0507984B8 (pt) 2023-03-21
HRP20070510T3 (hr) 2007-12-31
RU2369608C2 (ru) 2009-10-10
CN100503605C (zh) 2009-06-24
KR101080029B1 (ko) 2011-11-04
CA2557538A1 (en) 2005-09-01
DK2119715T3 (da) 2012-09-10
DK1857457T3 (da) 2009-12-21
PT2119715E (pt) 2012-09-03
SI2119715T1 (sl) 2012-10-30
EP1718641B1 (en) 2007-08-15
WO2005080384A3 (en) 2006-09-28
AU2005214271A1 (en) 2005-09-01
RS51137B (sr) 2010-10-31
AU2005214271B2 (en) 2011-02-24
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
EP1857457A2 (en) 2007-11-21
FR12C0034I2 (fr) 2013-01-11
EP1857457B1 (en) 2009-08-19
ATE440095T1 (de) 2009-09-15
JP2009137974A (ja) 2009-06-25
ES2331209T3 (es) 2009-12-23
CY1113084T1 (el) 2016-04-13
MY142807A (en) 2011-01-14
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
RS50537B (sr) 2010-05-07
RS52376B (en) 2012-12-31
RU2009115498A (ru) 2010-10-27
HK1115118A1 (en) 2008-11-21
IL177533A0 (en) 2006-12-10
DK1718641T3 (da) 2007-12-17
CY2012016I1 (el) 2016-12-14
NO20064251L (no) 2006-11-22
PL1718641T3 (pl) 2008-01-31
TWI336702B (en) 2011-02-01
ZA200607241B (en) 2008-04-30
BR122012009489B8 (pt) 2023-03-21
BE2012C025I2 (es) 2024-08-08
IL177533A (en) 2010-12-30
AU2005214271B8 (en) 2011-03-03
ATE370136T1 (de) 2007-09-15
NO2012017I2 (no) 2012-11-09
US20050187269A1 (en) 2005-08-25
AR094588A2 (es) 2015-08-12
DE602005016162D1 (de) 2009-10-01
EP1718641A2 (en) 2006-11-08
DE602005002030D1 (de) 2007-09-27
EP2119715B1 (en) 2012-05-30
PL1857457T3 (pl) 2009-12-31
US7875637B2 (en) 2011-01-25
LU91962I2 (fr) 2012-05-21
CY2012015I1 (el) 2016-12-14
ME01643B (me) 2010-05-07
CA2557538C (en) 2010-08-17
PT1857457E (pt) 2009-09-23
RU2006133898A (ru) 2008-03-27
HUS1200008I1 (hu) 2017-06-28
CY1107008T1 (el) 2012-09-26
DE602005002030T2 (de) 2008-05-08
BRPI0507984B1 (pt) 2018-07-03
ME01089B (me) 2013-03-20
BR122012009489B1 (pt) 2019-02-19
BRPI0507984A (pt) 2007-07-24
US20090270464A1 (en) 2009-10-29
US20060281795A1 (en) 2006-12-14
CY2012015I2 (el) 2016-12-14
US7157584B2 (en) 2007-01-02
NO2012017I1 (no) 2012-11-26
WO2005080384A9 (en) 2006-11-30
FR12C0034I1 (fr) 2012-06-15
TW200530227A (en) 2005-09-16
WO2005080384A2 (en) 2005-09-01
CY2012016I2 (el) 2016-12-14
ES2293552T3 (es) 2008-03-16
PT1718641E (pt) 2007-11-15
RU2501798C2 (ru) 2013-12-20
HRP20090593T1 (hr) 2010-03-31
CN1946717A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PL1613315T3 (pl) Pochodne chinolino-2-onu do leczenia chorób dróg oddechowych
PE20091843A1 (es) Inhibidores de catepsina c
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
JO2910B1 (en) Organic compounds
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
ATE543494T1 (de) Griseofulvin-analoga zur behandlung von krebs durch hemmung von zentrosomaler clusterbildung
EP2826472A3 (en) Telomerase activating compounds and their use
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
ATE540667T1 (de) Verbindungen mit kühlender wirkung
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
EA201070250A1 (ru) Противомикробный парентеральный состав
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования
RU2012150795A (ru) Композиция для борьбы с заболеваниями растений и ее применение описание
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
PE20141168A1 (es) Derivados de pirazolidin-3-ona

Legal Events

Date Code Title Description
FG Grant, registration